Evidence map›Paper›PMID 41571778›Full record

Observational studyScientific reports2026

Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study.

Charlène Lefèvre, Théo Funck-Brentano, Marine Cachanado, Alexia Plocque, Maëlle Youinou, Audrey Fels, Frédéric Pène, Laurent Savale, David Montani, Olivier Voisin and 12 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05017441 (TOcilizumab and Covid-19), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05017441 unknown statusnot on this map

TOcilizumab and Covid-19 : Risk of Severe INfection

TypeobservationalSponsorFondation Hôpital Saint-JosephRan2021 to 2024Enrolled1,200ConditionsCovid19
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Charlène LefèvreMedical and Surgical Intensive Care Department, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0000-0001-7349-6113
Théo Funck-BrentanoMedical and Surgical Intensive Care Department, Paris Saint Joseph Hospital, Paris, France.
Marine CachanadoDepartment of Clinical Research, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0000-0002-9739-7950
Alexia PlocqueMedical and Surgical Intensive Care Department, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0000-0003-0932-6739
Maëlle YouinouDepartment of Clinical Research, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0009-0002-9285-6203
Audrey FelsDepartment of Clinical Research, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0000-0001-5179-7644
Frédéric PèneMedical Intensive Care Department, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-3639-3849
Laurent SavaleDepartment of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-6862-8975
David MontaniDepartment of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-9358-6922
Olivier VoisinDepartment of Internal Medicine, Groupe Hospitalier Paris Saint Joseph, Paris, France.ORCID http://orcid.org/0000-0001-6802-9545
Flore BinteinDepartment of Pneumology-Allergology-Thoracic Oncology, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0000-0002-0202-6736
Lucille WildenbergDepartment of Anesthesiology, Intensive Care and Perioperative Medicine, Assistance Publique Hôpitaux de Paris, Paris Saclay University, 78 Rue du Général Leclerc, 94275, Le Kremlin-Bicêtre Cedex, France.ORCID http://orcid.org/0000-0002-0438-5169
Axel PhilippeDepartment of Anaesthesia and Intensive Care, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
Stéphane LegrielIntensive Care Unit, Versailles Hospital, Versailles, France.ORCID http://orcid.org/0000-0003-4782-6734
Nicolas RocheDepartment of Respiratory and Intensive Care Medicine, Assistance Publique - Hopitaux de Paris, Hôpital Cochin, Paris, Île-de-France, France.ORCID http://orcid.org/0000-0002-3162-5033
Pierre-Régis BurgelRespiratory Medicine and Cystic Fibrosis National Reference Center, AP-HP, Université Paris Cité, Cochin HospitalParis, France.ORCID http://orcid.org/0000-0003-0903-9828
Marc TranMedical and Surgical Intensive Care Department, Paris Saint Joseph Hospital, Paris, France.
Nicolas NoëlAP-HP, Service de Internal Medicine and Clinical Immunology, Paris-Saclay University, Bicêtre Hospital, DMU 7 Endocrinology-Immunity-Inflammation-Cancer-Emergencies, Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0003-4055-617X
Christophe BaillardDepartment of Anaesthesia and Intensive Care, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID http://orcid.org/0000-0003-3093-1378
Jacques DuranteauDepartment of Anesthesiology, Intensive Care and Perioperative Medicine, Assistance Publique Hôpitaux de Paris, Paris Saclay University, 78 Rue du Général Leclerc, 94275, Le Kremlin-Bicêtre Cedex, France.ORCID http://orcid.org/0000-0003-1902-2624
Gilles ChatellierDepartment of Clinical Research, Paris Saint Joseph Hospital, Paris, France.ORCID http://orcid.org/0000-0002-6373-8956
Francois PhilippartMedical and Surgical Intensive Care Department, Paris Saint Joseph Hospital, Paris, France. fphilippart@ghpsj.fr.ORCID http://orcid.org/0000-0002-7323-0742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During severe and critical COVID-19, therapeutic options remain scarce. Among interventions, the use of interleukin-6 receptor inhibitor (IL-6Ri) is especially controversial due to persistent uncertainty about their efficacy and safety. To compare the occurrence of secondary infections, digestive and hematological complication function of the administration of IL-6Ri we conducted a multicentric retrospective French observational study. All severe or critical COVID-19 requiring hospital admission were included. Among 2587 patients requiring hospital admission, 1603 had a severe COVID-19 and 984 a critical one requiring ICU admission. 224 received at least one dose of tocilizumab or sarilumab. Incidence of secondary infection was 29.5% in the IL-6Ri group vs. 19.5% without IL-6Ri (p = 0.0004) in the whole population. This result remained consistent after adjustment, without multiple imputation (MI) and after MI (adjusted OR: 1.47 [1.25; 1.72]; p < 0.0001)). Incidence of hematological or digestive complication were similar between groups. Mortality of patients admitted in ward was higher in the IL-6Ri group (18.7% vs 10.5%, p = 0.0155). No difference in 28 days, ICU, hospital of 90 days mortality was noticed among ICU patients.Clinical trial registration: This study was registred on ClinicalTrial.gov: NCT05017441.

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19COVID-19 Drug TreatmentReceptors, Interleukin-6AgedFemaleFranceHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Antibodies, Monoclonal, HumanizedReceptors, Interleukin-6sarilumabtocilizumabCovid-19MortalityNeutropeniaNosocomial infectionsTocilizumabVentilator-associated pneumonia

Identifiers

PMID41571778
PMCPMC12901058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.